Why the study?
What are the clinical advantages of atrial synchronous ventricular inhibited (ASVIP) pacemakers compared to A-V sequential (DVI) and atrial synchronous (VAT) systems in patients requiring pacing?
What are the clinical advantages of atrial synchronous ventricular inhibited (ASVIP) pacemakers compared to A-V sequential (DVI) and atrial synchronous (VAT) systems in patients requiring pacing?
Answers are grounded in this paper and cite their sources.
This early clinical evaluation describes the technical specifications and clinical advantages of ASVIP pacemakers compared to DVI and VAT systems in 30 patients.
The technical specifications and the operation of two atrial synchronous ventricular inhibited (ASVIP) pacemaker designs are described along with the results of clinical evaluation of these pacemakers in 30 patients. Clinical advantages of such pacemakers are contrasted with the performance of A-V sequential (DVI) and atrial synchronous (VAT) systems.
No takes yet. Share an insight, caveat, or question.
Kruse et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: